The effects of increased cAMP content on inflammation, oxidative stress and PDE4 transcripts during Brucella melitensis infection

Research in Veterinary Science

Volumn 84, Issue 1, 2008, Pages 18-25

  Erdogan, Suat ^a   Aslantas, Ozkan ^a   Celik, Sefa ^a   Atik, Esin ^a  

^a MUSTAFA KEMAL UNIVERSITY   (Turkey)

Author keywords

Brucella melitensis; Cytokine; Forskolin; IBMX; Lipid peroxidation; Oxidative stress; PDE4; Phosphodiesterase

Indexed keywords

ADENYLATE CYCLASE; ANTIOXIDANT; CYCLIC AMP; DEXAMETHASONE; FORSKOLIN; GAMMA INTERFERON; GLUTATHIONE PEROXIDASE; INTERLEUKIN 10; INTERLEUKIN 12; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IVB; PHOSPHODIESTERASE IVD; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; XANTHINE OXIDASE;

ANIMAL TISSUE; ARTICLE; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; HISTOPATHOLOGY; HYDROLYSIS; IMMUNOCOMPETENT CELL; INFLAMMATION; INOCULATION; INTRACELLULAR SPACE; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; SPLEEN;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; BRUCELLA MELITENSIS; BRUCELLOSIS; CYCLIC AMP; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; LIPID PEROXIDATION; LIVER; MALE; OXIDATIVE STRESS; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; SPLEEN; TRANSCRIPTION, GENETIC;

ANIMALIA; BRUCELLA; BRUCELLA MELITENSIS; RATTUS;

EID: 36049050697     PISSN: 00345288     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rvsc.2007.02.003     Document Type: Article

References (38)

1. Abdollahi M., Bahreini-Moghadam A., Emami B., Fooladian F., and Zafari K. Increasing intracellular cAMP and cGMP inhibits cadmium-induced oxidative stress in rat submandibular saliva. Comparative Biochemistry and Physiology: Part C, Pharmacology, Toxicology and Endocrinology 135C (2003) 331-336
2. Ahlstrom M., Pekkinen M., Huttunen M., and Lamberg-Allardt C. Dexamethasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochemical Pharmacology 69 (2005) 267-275
3. Aronoff D.M., Canetti C., Serezani C.H., Luo M., and Peters-Golden M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. The Journal of Immunology 174 (2005) 595-599
4. Baldwin C.L., and Parent M. Fundamentals of host immune response against Brucella abortus: what the mouse model has revealed about control of infection. Veterinary Microbiology 90 (2002) 367-382
5. Barber R., Baillie G.S., Bergmann R., Shepherd M.C., Sepper R., Houslay M.D., and Heeke G.V. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. American Journal of Physiology: Lung Cellular and Molecular Physiology 287 (2004) L332-L343
6. Bolger G.B., Rodgers L., and Riggs M. Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149 (1994) 237-244
7. Bos J.L. Epac: a new cAMP target and new avenues in cAMP research. Nature Reviews: Molecular and Cellular Biology 4 (2003) 733-738
8. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72 (1976) 248-254
9. Caron E., Peyrard T.U., Köhler S., Cabane S., Liautard J.-P., and Dornand J. Live Brucella spp. fail to induce tumor necrosis factor alpha excretion upon infection of U937-derived phagocytes. Infection and Immunity 62 (1994) 5267-5274
10. Caron E., Gross A., Liautard J.P., and Dornand J. Brucella species release a specific, protease-sensitive, inhibitor of TNF-alpha expression, active on human macrophage-like cells. Journal of Immunology 156 (1996) 2885-2893
11. Erdogan S., Celik S., Aslantas O., Kontas T., and Ocak S. Elevated cAMP levels reverse Brucella melitensis-induced lipid peroxidation and stimulate IL-10 transcription in rats. Research in Veterinary Science 82 (2007) 181-186
12. Fernandez-Lago L., Rodriguez-Tarazona E., and Vizcaino N. Differential secretion of interleukin-12 (IL-12) subunits and heterodimeric IL-12p70 protein by CD-1 mice and murine macrophages in response to intracellular infection by Brucella abortus. Journal of Medical Microbiology 48 (1999) 1065-1073
13. Gamazo C., Lecaroz M.C., Prior S., Vitas A.I., Campanero M.A., Irache J.M., and Blanco-Prieto M.J. Chemical and biological factors in the control of Brucella and brucellosis. Current Drug Delivery 3 (2006) 359-365
14. Gross A., Bertholet S., Mauel J., and Dornand J. Impairment of Brucella growth in human macrophagic cells that produce nitric oxide. Microbial Pathogenesis 36 (2004) 75-82
15. Hill E.V., Sheppard C.L., Cheung Y.F., Gall I., Krause E., and Houslay M.D. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579. Cellular Signalling 18 (2006) 2056-2069
16. Hort G.M., Weisenburger J., Borsdorf B., Peters C., Banai M., Hahn H., Jacob J., and Mielke M.E. Delayed type hypersensitivity-associated disruption of splenic periarteriolar lymphatic sheaths coincides with temporary loss of IFN-gamma production and impaired eradication of bacteria in Brucella abortus-infected mice. Microbes and Infection 5 (2003) 95-106
17. Houslay M.D., and Adams D.R. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochemical Journal 370 (2003) 1-18
18. Houslay M.D., and Kolch W. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Molecular Pharmacology 58 (2000) 659-668
19. Jiang X., Leonard B., Benson R., and Baldwin C.L. Macrophage control of Brucella abortus: Role of reactive oxygen intermediates and nitric oxide. Cellular Immunology 151 (1993) 309-319
20. Kenakin T.P., and Beek D. Measurement of antagonist affinity for purine receptors of drugs producing concomitant phosphodiesterase blockade: the use of pharmacologic resultant analysis. The Journal of Pharmacology and Experimental Therapeutics 243 (1987) 482-486
21. Kohda Y., and Gemba M. Modulation by cyclic AMP and phorbol myristate acetate of cephaloridine-induced injury in rat renal cortical slices. Japanese Journal of Pharmacology 85 (2001) 54-59
22. Kostic M.M., Erdogan S., Rena G., Borchert G., Hoch B., Bartel S., Scotland G., Huston E., Houslay M.D., and Krause E.G. Altered expression of PDE1 and PDE4 cyclic nucleotide phosphodiesterase isoforms in 7-oxo-prostacyclin-preconditioned rat heart. Journal of Molecular and Cellular Cardiology 29 (1997) 3135-3146
23. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacology and Therapeutics 109 (2006) 366-398
24. Lynch M.J., Hill E.V., and Houslay M.D. Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Current Topics in Developmental Biology 75 (2006) 225-259
25. Melek I.M., Erdogan S., Celik S., Aslantas O., and Duman T. Evaluation of oxidative stress and inflammation in long term Brucella melitensis infection. Molecular and Cellular Biochemistry 293 (2006) 203-209
26. Milani E., Nikfar S., Khorasani R., Zamani M.J., and Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comparative Biochemistry and Physiology. Toxicology & Pharmacology 140 (2005) 251-255
27. Nemoz G., Sette C., and Conti M. Selective activation of rolipram-sensitive, cAMP-specific phosphodiesterase isoforms by phosphatidic acid. Molecular Pharmacology 51 (1997) 242-249
28. Philippot L. Denitrification in pathogenic bacteria: for better or worst?. Trends in Microbiology 13 (2005) 191-192
29. Prajda N., and Weber G. Malignant transformation-linked imbalance: decreased XO activity in hepatomas. FEBS Letters 59 (1975) 245-249
30. Rodriguez-Zapata M., Salmeron I., Manzano L., Salmeron O.J., Prieto A., and Alvarez-Mon M. Defective interferon-gamma production by T-lymphocytes from patients with acute brucellosis. European Journal of Clinical Investigation 26 (1996) 136-140
31. Stabel T.J., Sha Z., and Mayfield J.E. Periplasmic location of Brucella abortus Cu/Zn superoxide dismutase. Veterinary Microbiology 38 (1994) 307-314
32. Stokol T., O'Donnell P., Xiao L., Knight S., Stavrakis G., Botto M., von Andrian U.H., and Mayadas T.N. C1q governs deposition of circulating immune complexes and leukocyte Fcgamma receptors mediate subsequent neutrophil recruitment. The Journal of Experimental Medicine 200 (2004) 835-846
33. Sun Y., Oberleyi L.W., and Ying L. A simple method for clinical assay of superoxide dismutase. Clinical Chemistry 34 (1988) 497-500
34. Tasken K., and Aandahl E.M. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiological Reviews 84 (2004) 137-167
35. Tatum F.M., Detilleux P.G., Sacks J.M., and Halling S.M. Construction of Cu-Zn superoxide dismutase deletion mutants of Brucella abortus: analysis of survival in vitro in epithelial and phagocytic cells and in vivo in mice. Infection and Immunity 60 (1992) 2689-2863
36. Taube M., and Carlsten H. Action of dexamethasone in the suppression of delayed-type hypersensitivity in reconstituted SCID mice. Inflammation Research 49 (2000) 548-552
37. Yoshoiko T., Kawada K., and Shimada T. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. American Journal of Obstetrics and Gynecology 135 (1979) 372-376
38. Zhan Y., and Cheers C. Endogenous interlekin-12 is involved in resistance to Brucella abortus infection. Infection and Immunity 63 (1995) 1387-1390